An article published in Contemporary Pediatrics 25 years ago instructed pediatricians on medications to treat attention deficit disorders (ADD). Their observations were so perceptive that, with a few tweaks, they could be republished as a 2009 update on attention deficit/hyperactivity disorder (ADHD).
The FDA has approved a new type of drug, an alpha-2A adrenergic receptor agonist, to treat ADHD in children as young as six.
Teva is now selling generic versions of Shire Plc's ADHD drug Adderall XR in the US, years before its patent expires.
Young people with ADHD may be at increased risk of becoming addicted to tobacco, according to a report in the Journal of Pediatrics.
Tobacco smoke and lead exposure may be linked to a particularly high risk of ADHD, according to findings presented at the 2008 Annual Meeting of the Society for Developmental and Behavioral Pediatrics.
The American Academy of Pediatrics (AAP) has stated it does not support the routine use of electrocardiogram (ECG) screening before initiating treatment with stimulants for children and adolescents with attention deficit hyperactivity disorder (ADHD).
ADHD diagnoses for children ages 6 to 17 have on average increased 3% per year from 1997 through 2006, according to the Centers for Disease Control and Prevention (CDC).
A reader comments on the lack of supporting evidence for the benefits of ADHD stimulants for children.
Resources for child ADHD.
A guide for parents about managing their child's ADHD.